You asked:
Please indicate the number of metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.
1. Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated
2. Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive, please indicate the number treated with the following therapies.
Cisplatin (mono or combination therapy)
Carboplatin (mono or combination therapy)
Pembrolizumab (Keytruda)
Atezolizumab (Tecentriq)
If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred: